Abstract: Sorafenib (BAY 43-9006) is a broad-spectrum, oral multikinase inhibitor and a cornerstone first-line targeted therapy for advanced hepatocellular carcinoma (HCC). While its classical anti-tumor efficacy is attributed to the inhibition of angiogenesis and cell proliferation pathways, recent evidence highlights its unique capacity to induce ferroptosis—an iron-dependent, non-apoptotic form of regulated cell death driven by lipid peroxidation. This review synthesizes the pharmacological activity and molecular mechanisms of sorafenib, with a specific focus on its role as a Class 1 ferroptosis inducer (FIN) that targets the system Xc-/SLC7A11 axis. Furthermore, it examines the structure-activity context of the drug and addresses current clinical limitations, primarily the rapid emergence of drug resistance mediated by epigenetic, transcriptomic, and metabolic reprogramming. Finally, future perspectives are discussed, emphasizing the potential of nanomedicine delivery systems and novel combination therapies designed to resensitize HCC cells to sorafenib-induced ferroptosis and improve patient outcomes.
1. Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with a majority of patients diagnosed at advanced stages where surgical resection is no longer viable [1]. Sorafenib (BAY 43-9006) is an FDA-approved oral multikinase inhibitor that established a breakthrough as a standard first-line systemic treatment for advanced HCC, significantly extending median overall survival [1][3]. Despite its initial efficacy, the clinical benefits of sorafenib are frequently curtailed by the rapid development of acquired drug resistance, which typically emerges within six months of treatment [1]. Recent advancements in molecular oncology have identified regulated cell death (RCD)—specifically ferroptosis—as a critical mechanism underlying both the therapeutic efficacy of sorafenib and the complex pathways of tumor resistance [1][2]. Ferroptosis is a non-apoptotic procedure characterized by the iron-dependent accumulation of lethal lipid peroxides [2]. Understanding how sorafenib regulates ferroptosis is essential for overcoming resistance and optimizing HCC therapy.
2. Pharmacological Activity
Sorafenib exhibits potent, broad-spectrum anti-tumor activity by simultaneously targeting multiple kinase pathways involved in tumor cell proliferation and tumor angiogenesis [1][5]. Its anti-angiogenic effects are achieved by inhibiting receptor tyrosine kinases (RTKs) on the cell surface, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor beta (PDGFR-beta), Flt3, and c-KIT [1][3][5]. By blocking these receptors, sorafenib disrupts neovascularization, depriving the tumor of essential oxygen and nutrients [5]. Concurrently, sorafenib exerts anti-proliferative effects by inhibiting intracellular serine/threonine kinases, specifically Raf-1 and B-Raf, thereby blocking the downstream MEK/ERK signaling cascade [1][5]. Additionally, it modulates the PI3K/Akt/mTOR pathway and downregulates hypoxia-inducible factor-1 alpha (HIF-1α) [5]. Beyond its kinase inhibitory profile, sorafenib is pharmacologically classified as a Class 1 ferroptosis inducer (FIN), a property that significantly contributes to its cytotoxicity in HCC [9].
3. Molecular Mechanism of Action
The regulation of ferroptosis by sorafenib involves a multi-faceted disruption of cellular redox homeostasis, lipid metabolism, and iron utilization:
System Xc- and GPX4 Pathway: Sorafenib induces ferroptosis primarily by inhibiting system Xc-, a heterodimeric amino acid transporter. Specifically, it blocks the solute carrier family 7 member 11 (SLC7A11) subunit, preventing the cellular uptake of extracellular cystine [2][9]. This blockade leads to the depletion of intracellular cysteine and subsequently glutathione (GSH). The loss of GSH impairs the activity of glutathione peroxidase 4 (GPX4), an enzyme responsible for detoxifying lipid hydroperoxides, ultimately triggering ferroptotic cell death [2].
Lipid Peroxidation: In the absence of GPX4-mediated detoxification, polyunsaturated fatty acids (PUFAs) esterified into phospholipids undergo pathological peroxidation [2]. Sorafenib's efficacy is tightly linked to this lipid peroxidation process. Conversely, metabolic reprogramming that increases monounsaturated fatty acids (MUFAs) via the HBXIP/SCD axis can impede sorafenib-induced ferroptosis [4].
Iron Dependency: Sorafenib-induced oxidative stress is strictly dependent on the intracellular labile iron pool. Highly oxidized iron (Fe2+) generates toxic hydroxyl radicals via the Fenton reaction, driving lipid peroxidation [2]. Experimental depletion of intracellular iron stores using the iron chelator deferoxamine (DFX) strikingly protects HCC cells from sorafenib-induced cytotoxicity, confirming that iron-dependent oxidative stress is a primary mechanism of its anti-tumor action [1].
4. Structure-Activity Relationship (SAR)
Sorafenib (BAY 43-9006) is structurally designed as a multikinase inhibitor capable of binding to the ATP-binding pockets of various intracellular kinases (e.g., Raf) and cell surface receptors (e.g., VEGFR, PDGFR) [1][3]. Interestingly, compared to other clinically relevant kinase inhibitors, sorafenib is unique in its ability to display potent ferroptotic efficacy [1]. This indicates that specific structural moieties within the sorafenib molecule confer a dual mechanism of action: classical kinase inhibition and the off-target blockade of the SLC7A11 transporter [1][9]. While it shares the Class 1 FIN designation with compounds like erastin and sulfasalazine, sorafenib's distinct structural profile allows it to be utilized effectively in vivo, unlike erastin which suffers from poor metabolic stability [9].
5. Current Limitations
The clinical utility of sorafenib is hindered by significant limitations, primarily pharmacokinetic challenges and the rapid onset of drug resistance:
Pharmacokinetics and Toxicity: Sorafenib suffers from poor aqueous solubility and rapid systemic clearance, necessitating high dosing regimens. This often leads to dose-limiting systemic toxicities, including hand-foot syndrome, hypertension, and gastrointestinal issues [5].
Resistance via Ferroptosis Evasion: HCC cells employ extensive epigenetic and metabolic reprogramming to counteract sorafenib-induced ferroptosis [2].
Key resistance mechanisms include:
- SLC7A11 Upregulation: Epigenetic regulators such as YAP/TAZ maintain SLC7A11 stability, preventing ferroptosis [6]. Additionally, long non-coding RNAs (lncRNAs) like CASC11, DUXAP8, and MALAT1, as well as circular RNAs (circTTC13), upregulate SLC7A11 expression to restore system Xc- activity [2].
- Lipid Metabolism Alteration: Upregulation of miR-23a-3p inhibits ACSL4, a key enzyme for PUFA activation, thereby blocking lipid peroxidation [2]. Furthermore, the lncRNA HNF4A-AS1 and the HBXIP/SCD axis reprogram lipid metabolism to deplete PUFAs or increase MUFAs, conferring resistance [2][4].
- Iron Regulation: Downregulation of transferrin receptors (TFR1/TFR2) via miR-654-5p or EZH2 reduces intracellular iron uptake, inhibiting the Fenton reaction and protecting cells from sorafenib [2]. Furthermore, metallothionein-1G (MT-1G) expression is triggered by sorafenib and acts as a critical negative regulator of ferroptosis [1].
6. Future Perspectives
To overcome the limitations of sorafenib, current research is heavily focused on advanced delivery systems and rational combination therapies:
Nanomedicine: Nanoparticle (NP) delivery systems—including liposomes, polymeric NPs, and stimuli-responsive (pH/GSH) platforms—are being engineered to improve sorafenib's bioavailability, enable targeted tumor accumulation, and minimize systemic toxicity [5]. Innovative approaches include co-delivering sorafenib with superparamagnetic iron oxide nanoparticles (SPIONs) to synergistically induce lipid hydroperoxides and overwhelm the tumor's ferroptosis defense mechanisms [8].
Combination Therapies: Targeting the epigenetic and metabolic pathways that suppress ferroptosis offers a promising strategy to resensitize resistant HCC cells. Pharmacological inhibition of targets like MALAT1, PLAG1, or fatty acid synthase (FASN) has demonstrated synergistic anti-tumor efficacy when combined with sorafenib [2][4]. Additionally, combining sorafenib with natural compounds or immune checkpoint inhibitors is being actively explored to modulate the tumor microenvironment and enhance overall therapeutic outcomes [5][8].
